VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
+28.34%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$1B
AUM Growth
+$1B
(+18%)
Cap. Flow
-$42.9M
Cap. Flow
% of AUM
-4.28%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
–
Reduced
1
Closed
1
Top Buys
No buys this quarter
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$26M |
| 2 |
Harmony Biosciences
HRMY
|
$16.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ALX Oncology
ALXO
$62.7M
| $716M | 71.37% | 9,699,925 | – | – |
|
|
2
Harmony Biosciences
HRMY
$2.12B
| $117M | 11.7% | 3,063,194 -441,430 | -13% | -$16.9M |
|
3
Akero Therapeutics
AKRO
$3.74B
| $49.2M | 4.9% | 2,200,778 | – | – |
|
4
Pharvaris
PHVS
$1.39B
| $40.8M | 4.07% | 2,303,310 | – | – |
|
|
IMPL
5
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $33.6M | 3.35% | 2,759,791 | – | – |
|
|
ELEV
6
DELISTED
Elevation Oncology
ELEV
| $20.3M | 2.02% | 2,608,167 | – | – |
|
|
CMPI
7
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $14.6M | 1.45% | 3,673,374 | – | – |
|
|
MTCR
8
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $10.5M | 1.05% | 3,059,123 | – | – |
|
|
VRNA
9
Verona Pharma
VRNA
$9.16B
| $887K | 0.09% | 161,897 | – | – |
|
|
10
Apellis Pharmaceuticals
APLS
$3.48B
| – | – | -411,471 | Closed | -$26M |
|